Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC

Exclusion Criteria

• •1. Patients who had previously used antiangiogenic agents within 1 month;
• •2. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
• •3. Patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small cell lung cancer with hemoptysis;
• •4. Patients with cerebral infarction and cerebral hemorrhage;
• •5. Patients without perilesional edema；
• •6. Patients with more than grade 2 (NCI-CTCAE v4.0) acute toxicity reaction due to any previous treatment.
• •7. Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.);
• •8. Patients with visceral dissemination or severe symptoms, which could cause death in short term;
• •9. Patients with any other severe and/or uncontrolled disease;
• •10. Patients who received a surgery, a biopsy or a significant traumatic injury within 1 month;
• •11. Patients with any signs or medical history of bleeding, unhealed wounds, ulcers or fractures, regardless of the severity;
• •12. Patients underwent artery or venous thrombotic events within 2 months, such as deep vein thrombosis and pulmonary embolism;
• •13. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;
• •14. Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；
• •15. Patients who still can't tolerate SRS after anlotinib treatment, even after adding mannitol, and have to receive steroid treatment.